The IPO4 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa human cervical adenocarcinoma cell line. These cells harbor a targeted disruption of the IPO4 gene, which encodes the nuclear transport receptor importin-4. This knockout model provides a heterogeneous and versatile tool for dissecting IPO4 functions in nucleocytoplasmic trafficking and cancer cell biology.
HeLa cells, originating from a cervical adenocarcinoma, are a widely used human epithelial cell line containing integrated HPV-18 sequences and an aneuploid genome. Their robust growth and well-documented biology make them an ideal host for investigating gene function in the context of HPV-driven carcinogenesis and fundamental cellular processes.
IPO4 (Importin-4) is a ??-importin family member that mediates nuclear import of cargo proteins bearing classical nuclear localization signals (NLS). Key substrates include histones H3 and H4, and transcription-associated factor TAF12. IPO4 binds its cargo in the cytoplasm and translocates through the nuclear pore complex via transient interactions with nucleoporins such as Nup153 and Nup50. Within the nucleus, RanGTP binding induces cargo release, while cytoplasmic RanGDP promotes cargo association. IPO4 expression and activity are influenced by upstream regulators including E2F transcription factors and the MAPK/ERK growth signaling pathway. The transport cycle involves coordinated action of RAN GTPase, NTF2, and importin-??, underscoring the complexity of nuclear import regulation.
In HeLa cells, which are derived from an HPV-18-positive cervical adenocarcinoma, IPO4 disruption can abrogate the nuclear localization of its specific cargos, thereby affecting cell cycle progression, transcriptional regulation, and overall cellular fitness. This model allows investigation of how altered nuclear transport contributes to the malignant phenotype and potential vulnerabilities in HPV-associated cancers.
Researchers can utilize this polyclonal knockout population in a range of assays, including immunofluorescence to monitor cargo mislocalization, Western blotting and RT-qPCR for target expression analysis, and RNA-seq transcriptomics. Functional evaluations like MTT viability, migration/invasion, and drug sensitivity assays enable assessment of proliferative and migratory capacity. Co-immunoprecipitation studies can further elucidate protein interaction networks. This cell model is suited for nuclear transport mechanistic studies, cancer biology research, and validation of nuclear transport inhibitors as therapeutic targets. For further information, please contact Ascent Research.
